|
US9453251B2
(en)
|
2002-10-08 |
2016-09-27 |
Pfenex Inc. |
Expression of mammalian proteins in Pseudomonas fluorescens
|
|
DE10254601A1
(de)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
|
|
EP2412816B1
(en)
|
2004-07-26 |
2014-12-03 |
Pfenex Inc. |
Process for improved protein expression by strain engineering
|
|
WO2007071422A2
(en)
*
|
2005-12-21 |
2007-06-28 |
Micromet Ag |
Pharmaceutical antibody compositions with resistance to soluble cea
|
|
WO2007071426A1
(en)
|
2005-12-21 |
2007-06-28 |
Micromet Ag |
Pharmaceutical compositions with resistance to soluble cea
|
|
EP2615172A1
(en)
|
2007-04-27 |
2013-07-17 |
Pfenex Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
US9580719B2
(en)
|
2007-04-27 |
2017-02-28 |
Pfenex, Inc. |
Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
|
|
EP2225275A4
(en)
*
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
PROTEIN FORMULATION
|
|
GB0908613D0
(en)
*
|
2009-05-20 |
2009-06-24 |
Immunocore Ltd |
T Cell Reseptors
|
|
EP2478110B1
(en)
|
2009-09-16 |
2016-01-06 |
Immunomedics, Inc. |
Class i anti-cea antibodies and uses thereof
|
|
EP2507628A4
(en)
*
|
2009-12-01 |
2013-04-24 |
Medimmune Llc |
IMPROVED METHODS AND COMPOSITIONS FOR DETECTING AND TREATING CEA-EXPRESSING TUMORS
|
|
EP3252076B1
(en)
|
2011-01-14 |
2019-09-04 |
The Regents Of The University Of California |
Diagnostic use of antibodies against ror-1 protein
|
|
WO2013012414A1
(en)
*
|
2011-07-18 |
2013-01-24 |
Medimmune, Llc |
Dosing regimens for treatment of cea-expressing cancers
|
|
WO2013054320A1
(en)
*
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
|
US9783610B2
(en)
|
2012-04-27 |
2017-10-10 |
The Trustees Of The University Of Pennsylvania |
Anti-tumor endothelial marker-1 (TEM1) antibody variants and uses thereof
|
|
WO2013174404A1
(en)
*
|
2012-05-23 |
2013-11-28 |
Ganymed Pharmaceuticals Ag |
Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
|
|
US20150231241A1
(en)
|
2012-08-14 |
2015-08-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
EP2885002A4
(en)
|
2012-08-14 |
2016-04-20 |
Ibc Pharmaceuticals Inc |
BISPECIFIC ANTIBODIES REDIRECTED AGAINST T CELLS FOR THE TREATMENT OF DISEASES
|
|
US9682143B2
(en)
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
NZ746691A
(en)
|
2012-11-13 |
2020-08-28 |
Astellas Pharma Inc |
Agents for treatment of claudin expressing cancer diseases
|
|
SI2922875T1
(sl)
|
2012-11-20 |
2017-06-30 |
Sanofi |
Protitelesa anti-CEACAM5 in njihove uporabe
|
|
CN110845618A
(zh)
|
2013-02-26 |
2020-02-28 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
UA119320C2
(uk)
*
|
2013-02-26 |
2019-06-10 |
Рош Глікарт Аг |
Активуюча т-клітини біспецифічна антигензв'язувальна молекула
|
|
SI2970449T1
(sl)
|
2013-03-15 |
2019-11-29 |
Amgen Res Munich Gmbh |
Enoverižne vezavne molekule, ki vsebujejo N-terminalni ABP
|
|
EP2930188A1
(en)
*
|
2014-04-13 |
2015-10-14 |
Affimed Therapeutics AG |
Trifunctional antigen-binding molecule
|
|
US11427647B2
(en)
|
2014-04-27 |
2022-08-30 |
Famewave Ltd. |
Polynucleotides encoding humanized antibodies against CEACAM1
|
|
AP2016009504A0
(en)
|
2014-04-27 |
2016-10-31 |
Ccam Biotherapeutics Ltd |
Humanized antibodies against ceacam1
|
|
MX2016017393A
(es)
|
2014-07-01 |
2017-09-05 |
Pfizer |
Diacuerpos heterodimericos biespecificos y sus usos.
|
|
AU2016222830B2
(en)
|
2015-02-24 |
2021-02-25 |
Bioatla Llc |
Conditionally active biological proteins
|
|
CN106432502B
(zh)
*
|
2015-08-10 |
2020-10-27 |
中山大学 |
用于治疗cea阳性表达肿瘤的双特异纳米抗体
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
KR20180073561A
(ko)
|
2015-10-02 |
2018-07-02 |
에프. 호프만-라 로슈 아게 |
이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
|
|
ES2901794T3
(es)
|
2015-12-09 |
2022-03-23 |
Hoffmann La Roche |
Anticuerpo anti-CD20 de tipo II para reducir la formación de anticuerpos antifármaco
|
|
AR107303A1
(es)
|
2016-01-08 |
2018-04-18 |
Hoffmann La Roche |
Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
|
|
PT3464380T
(pt)
|
2016-06-02 |
2025-02-06 |
Immunocore Ltd |
Regime de dosagem para proteína de fusão de tcr específico de gp100 - scfv anti-cd3
|
|
CN107663240B
(zh)
*
|
2016-07-29 |
2021-01-12 |
中国人民解放军第四军医大学 |
高度糖基化cea特异性结合的单链抗体及其在检测和治疗上的应用
|
|
IL267284B2
(en)
|
2016-12-19 |
2023-03-01 |
Hoffmann La Roche |
Combination therapy with a targeted 4-bb1 agonist (cd137)
|
|
EP3565843A1
(en)
|
2017-01-03 |
2019-11-13 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
|
|
CN107056952A
(zh)
*
|
2017-05-10 |
2017-08-18 |
常州市第人民医院 |
Cea.car‑t及其制备与应用
|
|
CN107058234B
(zh)
*
|
2017-05-12 |
2019-09-13 |
常州市第一人民医院 |
Car.il-33-t及其制备与应用
|
|
EP3661555B1
(en)
|
2017-08-01 |
2025-04-16 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
CN111315781A
(zh)
|
2017-11-01 |
2020-06-19 |
豪夫迈·罗氏有限公司 |
用靶向性ox40激动剂的组合疗法
|
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
|
JP7403479B2
(ja)
|
2018-06-03 |
2023-12-22 |
ランカプ バイオ ベータ リミテッド |
Ｃｅａｃａｍ５およびｃｄ４７に対する二重特異性抗体
|
|
CN112424228B
(zh)
|
2018-07-04 |
2024-08-09 |
豪夫迈·罗氏有限公司 |
新型双特异性激动性4-1bb抗原结合分子
|
|
WO2020127618A1
(en)
|
2018-12-21 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Tumor-targeted agonistic cd28 antigen binding molecules
|
|
US12463463B2
(en)
|
2019-01-28 |
2025-11-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
EP3693023A1
(en)
|
2019-02-11 |
2020-08-12 |
Sanofi |
Use of anti-ceacam5 immunoconjugates for treating lung cancer
|
|
MX2021009514A
(es)
|
2019-02-07 |
2021-11-04 |
Sanofi Sa |
Uso de inmunoconjugados anti-ceacam5 para el tratamiento del cancer de pulmon.
|
|
IL288024B2
(en)
|
2019-05-14 |
2025-12-01 |
Provention Bio Inc |
Methods and compositions for preventing type
|
|
CA3142887A1
(en)
|
2019-06-13 |
2020-12-17 |
Bolt Biotherapeutics, Inc. |
Aminobenzazepine compounds, immunoconjugates, and uses thereof
|
|
EP3990492A1
(en)
*
|
2019-06-27 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
|
WO2021041300A2
(en)
*
|
2019-08-23 |
2021-03-04 |
Ab Therapeutics, Inc. |
Bispecific antibodies and uses thereof
|
|
WO2021046112A1
(en)
|
2019-09-03 |
2021-03-11 |
Bolt Biotherapeutics, Inc. |
Aminoquinoline compounds, immunoconjugates, and uses thereof
|
|
BR112022004995A2
(pt)
|
2019-09-18 |
2022-06-21 |
Lamkap Bio Alpha AG |
Anticorpos biespecíficos contra ceacam5 e cd3
|
|
WO2021067242A1
(en)
|
2019-09-30 |
2021-04-08 |
Bolt Biotherapeutics, Inc. |
Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
|
|
TWI857167B
(zh)
|
2019-10-25 |
2024-10-01 |
美商博特生物治療公司 |
噻吩并氮呯免疫結合物及其用途
|
|
WO2021098822A1
(zh)
*
|
2019-11-21 |
2021-05-27 |
江苏恒瑞医药股份有限公司 |
一种双特异性抗体
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
|
CA3176626A1
(en)
|
2020-05-08 |
2021-11-11 |
David Dornan |
Elastase-substrate, peptide linker immunoconjugates, and uses thereof
|
|
US12006366B2
(en)
|
2020-06-11 |
2024-06-11 |
Provention Bio, Inc. |
Methods and compositions for preventing type 1 diabetes
|
|
US20230263903A1
(en)
|
2020-08-13 |
2023-08-24 |
Bolt Biotherapeutics, Inc. |
Pyrazoloazepine immunoconjugates, and uses thereof
|
|
IL302731A
(en)
|
2020-11-10 |
2023-07-01 |
Sanofi Sa |
Formulation of an antibody-drug conjugate for CEACAM5
|
|
CA3200051A1
(en)
|
2020-12-11 |
2022-06-16 |
Shelley Erin ACKERMAN |
Anti-cea immunoconjugates, and uses thereof
|
|
US20220195066A1
(en)
|
2020-12-11 |
2022-06-23 |
Bolt Biotherapeutics, Inc. |
Anti-cea immunoconjugates, and uses thereof
|
|
RS65211B1
(sr)
|
2020-12-18 |
2024-03-29 |
Lamkap Bio Beta Ag |
Bispecifična antitela protiv ceacam5 i cd47
|
|
JP2024511088A
(ja)
|
2021-03-26 |
2024-03-12 |
ボルト バイオセラピューティクス、インコーポレーテッド |
２－アミノ－４－カルボキサミド－ベンゾアゼピン免疫複合体、及びその使用
|
|
IL306114A
(en)
|
2021-03-26 |
2023-11-01 |
Bolt Biotherapeutics Inc |
2-amino-4-carboxamide-benzazepine immunoconjugates and uses thereof
|
|
MX2023013851A
(es)
|
2021-05-24 |
2023-12-08 |
Provention Bio Inc |
Metodos para el tratamiento de diabetes tipo 1.
|
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
|
AU2023237620A1
(en)
|
2022-03-23 |
2024-08-29 |
Synaffix B.V. |
Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
|
|
KR20250025384A
(ko)
|
2022-06-16 |
2025-02-21 |
람카프 바이오 베타 엘티디. |
Ceacam5 및 cd47에 대한 이중특이적 항체 및 ceacam5 및 cd3에 대한 이중특이적 항체의 조합 요법
|
|
US20250043001A1
(en)
|
2023-03-14 |
2025-02-06 |
Xencor, Inc. |
Anti-cd28 compositions
|
|
WO2024261013A1
(en)
|
2023-06-21 |
2024-12-26 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted lymphotoxin beta receptor agonists
|